The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|May 3, 2022
Rheumatoid Arthritis Quiz: Maximizing the Benefits of at Treat-to-Target Strategy
Author(s)Ingrid Torjesen
The American College of Rheumatology recommends that a treat-to-target strategy is followed for rheumatoid arthritis. Test your knowledge of how to maximize the potential benefits of this approach with this quiz.
Advertisement
Which of the following is not a cornerstone of a treat-to-target strategy in rheumatoid arthritis?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement